29: PILOTING A LEAFLET TO IMPROVE PATIENT ENGAGEMENT WITH DO NOT ATTEMPT CARDIOPULMONARY RESUSCITATION (DNACPR) DECISIONS

29:试点推广宣传单以提高患者对“不进行心肺复苏术 (DNACPR)”决定的参与度

阅读:1

Abstract

AIMS: To characterize and compare modes of death and reasons for withdrawal of life-sustaining therapies (WLST) in children admitted to an intensive care unit (ICU) after in-hospital cardiac arrest (IHCA) or out-of-hospital cardiac arrest (OHCA). METHODS: Single center retrospective study of children who experienced IHCA or OHCA, were admitted to an ICU from January 2017 to March 2023, and died prior to discharge. Modes of death were classified as: a) death by neurologic criteria (DNC), b) WLST, c) recurrent arrest with attempted resuscitation ("recurrent arrest") or d) recurrent arrest without attempted resuscitation ("recurrent arrest/DNAR"). RESULTS: Of 746 patients receiving post-arrest care, 260 non-survivors were analyzed. Of 155 IHCA patients, mode of death was DNC 8 (5%), WLST 87 (56%), recurrent arrest 33 (21%), recurrent arrest/DNAR 27 (18%). The primary reason for WLST was poor cardiovascular prognosis (WLST-CV) (40/87 [46%]). Of 105 OHCA patients, mode of death was DNC 51 (49%), WLST 38 (36%), recurrent arrest 8 (7.5%), recurrent arrest/DNAR 8 (7.5%). The primary reason for WLST was poor neurologic prognosis (WLST-N) (32/38 [84%]). Compared to OHCA patients, children with IHCA were less likely to die from DNC (p < 0.001) and more often underwent WLST-CV (p < 0.001). The median time to death was longer for IHCA vs. OHCA (5 [0.8,30] vs 3 [1.5,6] days, p = 0.03). CONCLUSIONS: Following an IHCA, non-survivors more frequently died from circulatory failure, including WLST-CV or recurrent arrest, while OHCA non-survivors more frequently died from neurologic injury, including DNC and WLST-N. Children who had an IHCA died later after their arrest than those who had an OHCA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。